Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
This study has been completed.
Information provided by:
First received: November 15, 2005
Last updated: December 14, 2007
Last verified: December 2007
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
Obsessive Compulsive Disorder
Drug: quetiapine fumarate
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study|
Resource links provided by NLM:
Drug Information available for: Clomipramine Clomipramine hydrochloride Quetiapine Quetiapine fumarateU.S. FDA Resources
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.
Secondary Outcome Measures:
- Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
- Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.
|Study Start Date:||April 2002|
|Study Completion Date:||March 2006|
Contacts and Locations